(F04) Immune Checkpoint Inhibitor–Induced Autoimmune Diabetes: The Role of the CDCES

Cancer is a disease with a high mortality rate. Novel therapeutic modalities such as immunotherapies have emerged as supplements to conventional treatment. Immune checkpoint inhibitors (ICIs) substantially enhance tumor treatment outcomes by blocking key regulators of the immune system. For this reason, they are also associated with immune-related adverse events including induced autoimmune diabetes. This session will provide the DCES with the knowledge and tools needed for early detection and management necessary to prevent significant morbidity and mortality. It will also review the importance of glucose monitoring as well as patient and family education about this drug induced diabetes